Welcome to our dedicated page for Passage Bio SEC filings (Ticker: PASG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Passage Bio, Inc. (PASG) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical stage genetic medicines company listed on the Nasdaq Capital Market, Passage Bio uses SEC filings to report financial results, material corporate events, and key developments in its PBFT02 gene therapy program for neurodegenerative diseases.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to see detailed information on research and development and general and administrative expenses, net loss, cash, cash equivalents, and marketable securities, along with risk factor and business discussions. Form 8-K current reports document material events such as quarterly financial press releases, updated corporate presentations, program data updates from the upliFT-D trial, manufacturing and regulatory milestones, board and committee changes, and the implementation of the 1-for-20 reverse stock split and related Nasdaq listing matters.
Where applicable, investors may also consult proxy materials and other governance-related filings for information on board composition and stockholder approvals, including approvals related to capital structure changes. For a company like Passage Bio, which is advancing a gene therapy candidate through early-stage clinical development, these filings help clarify trial status, manufacturing strategy, and the company’s view of its cash runway and operating priorities.
On Stock Titan, Passage Bio filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand major changes in financial condition, clinical and regulatory plans, and capital structure. Real-time updates from EDGAR ensure that new PASG filings, including 10-K, 10-Q, and 8-K reports, appear promptly, while structured access to filings supports deeper review of the company’s regulatory and disclosure history.
Passage Bio, Inc. filed a current report to note it issued a press release announcing financial results for the quarter ended September 30, 2025 and updated its corporate presentation.
The press release is furnished under Item 2.02 as Exhibit 99.1, and the presentation is furnished under Item 7.01 as Exhibit 99.2. Both items are furnished, not filed, and are not incorporated by reference except as specifically stated. The report was signed by Chief Financial Officer Kathleen Borthwick.
Passage Bio, Inc. reported that on September 16, 2025, board member Saqib Islam resigned from its Board of Directors and from the Board’s Audit Committee, effective immediately. The company stated that his decision was not due to any disagreement with Passage Bio on matters related to operations, policies, or practices.
To address the vacancy, the Board appointed Athena Countouriotis, M.D., to serve on the Audit Committee and reduced the overall Board size from eight to seven members as of the resignation date.
Passage BIO, Inc. (PASG) Form 4: Lynx1 Capital Management LP and Weston Nichols reported insider purchases of Passage BIO common stock on three dates in September 2025. The filings show acquisitions of 325 shares on 09/11/2025 at a weighted average price of $6.9558 (range $6.915–$6.985), 19,783 shares on 09/12/2025 at $6.9908 (range $6.93–$7.00), and 11,900 shares on 09/15/2025 at $6.9895 (range $6.94–$7.00). Following these transactions, the filing reports beneficial ownership of 623,704 shares held indirectly through Lynx1 Master Fund LP, for which Lynx1 Capital Management LP is the investment manager and Weston Nichols is the sole member of the manager's GP. The reporting persons are identified as a director and a 10% owner.
Passage Bio reported a tighter but funded balance sheet with $57.6 million in cash and cash equivalents and total assets of $79.2 million, down from $102.4 million. The company recorded a net loss of $9.4 million for the quarter and $24.8 million for the six months, driven by research and development and general and administrative costs, partially offset by $0.9 million of other income in the quarter.
The company implemented a workforce reduction of about 55% and ceased laboratory operations in Hopewell, resulting in a $2.6 million impairment of long-lived assets and a subsequent sale of substantially all lab equipment for $1.2 million. Passage Bio received $9.7 million of non-refundable sublicense and transition services payments related to amended Gemma sublicenses (additional contractual payments and milestones disclosed) and has $15.8 million capacity remaining under its ATM facility. Management states cash is sufficient to fund operations for at least the next 12 months.
Passage Bio, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and updated its corporate presentation. The press release is attached as Exhibit 99.1 and the presentation as Exhibit 99.2.
The 8-K states these items are furnished, not filed, so they are not subject to Section 18 liability and will not be incorporated by reference into other filings except by specific reference. The text of the filing does not include any numeric financial figures or operational details; the detailed results and presentation slides are contained in the attached exhibits.
Insider buying: On 22-24 Jul 2025, 10% owner Lynx1 Capital Management LP, through Lynx1 Master Fund LP, bought a total of 128,848 Passage Bio (PASG) common shares in open-market transactions coded “P”. Weighted-average prices were $5.4361 (13,123 sh), $5.7408 (49,302 sh) and $5.7127 (66,423 sh), implying an aggregate cash outlay of roughly $0.72 million.
After the purchases, Lynx1’s indirect holding grew from 462,848 to 591,696 shares, a ~28% increase. The totals already reflect Passage Bio’s 1-for-20 reverse stock split effective 14 Jul 2025. No derivative securities were reported.
Weston Nichols, sole member of the investment manager’s GP, and the manager itself each disclaim beneficial ownership beyond their pecuniary interests.
Form 144 filing – Passage Bio, Inc. (PASG)
Investment fund OrbiMed Private Investments VII, LP intends to sell 132,645 common shares through Themis Trading LLC on or about 21 Jul 2025. The indicated aggregate market value is $737,506, implying an average price of roughly $5.56 per share. The block equals about 4.3 % of the 3,120,295 shares outstanding disclosed in the notice.
The same holder has already disposed of 1,142,565 shares in the past three months across 15 transactions, realising total gross proceeds of approximately $702,867. Combining completed and proposed sales, OrbiMed has moved or plans to move roughly 41 % of the reported outstanding share count, signalling an ongoing reduction of its stake that could add selling pressure to PASG shares.
No operational, earnings or strategic updates accompany the notice. The filer represents that it possesses no non-public material adverse information.